Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2021 · 10-Q
Revenue$8.07M$8.07Mno prior Q3 2020 on file Net Income-$1.06M-$1.06Mno prior Q3 2020 on file EPS Diluted-$0.07-$0.07no prior Q3 2020 on file Operating Income-$1,563,395— Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$161,961— Margins · derivedOperating margin-19.4%
Net margin-13.1%
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end